The lawsuit, filed in the U.S. District Court for the Northern District of California under the caption Robbins v. GRAIL, Inc., et al., claims the company violated federal securities laws by misrepresenting the trial’s ability to achieve its goals. GRAIL had marketed the NHS-Galleri trial as a landmark effort to prove that its blood-based screening could reduce late-stage cancer diagnoses. However, the company revealed on February 19, 2026, that the study failed to show a statistically significant reduction in Stage III-IV cancers.
GRAIL Faces Securities Class Action After NHS-Galleri Trial Failure
A 50.55% collapse in GRAIL, Inc. stock following the failure of its flagship cancer screening trial has triggered a securities fraud class action. Investors allege the company misled them regarding the design and viability of the NHS-Galleri study, which failed to meet its primary endpoint in February 2026.
While GRAIL executives previously touted the trial’s three-year design as sufficient, the company later attributed the disappointing results to a need for longer follow-up times. This disclosure wiped out over half of the company’s market value in a single day, as shares plummeted from $101.53 to $50.21. Bleichmar Fonti & Auld LLP, the firm representing the class, has set an August 4, 2026, deadline for investors to petition the court for lead plaintiff status.
Comments (0)
No comments yet. Be the first!